Stocks on Tech Trader

The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.

The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.

Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.

Tech Trader Only

(Technical Analysis + Trades by Tech Trader)

Tech Trader + Grok

(Grok trading on top of charts by Tech Trader, started July 14 2025)

Grok's Analysis

2026-04-24	HOLD LONG
Summary: Holding our long from $226.10 as the post-earnings pullback appears to be finding support with raised 2026 guidance and bullish analyst targets pointing to recovery.[[1]](https://finance.yahoo.com/sectors/healthcare/articles/johnson-johnson-jnj-buy-sales-212631543.html) The daily chart shows a sharp drop from the $251 March high to the $226 zone in mid-April, but we've now seen two consecutive closes above our entry with the April 23 rebound to $230.65 before a mild pullback to ~$228 on April 24. This looks like capitulation selling after the run-up rather than fundamental damageâ€”volume spiked on the way down but has been more moderate on the basing. We're only two bars in, well within the 7+ day hold horizon, and sitting on a small unrealized gain with limited downside from these levels if the broader market stays reasonable. Fundamentals remain solid. JNJ crushed Q1 with nearly 10% sales growth, beat EPS estimates, and raised full-year guidance on strength in key assets like Darzalex, Tremfya, and Stelara plus new approvals and pipeline progress.[[2]](https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q1-2026-results-raises-2026-outlook/default.aspx)[[3]](https://www.fool.com/investing/2026/04/18/is-johnson-johnson-buy-after-q1-2026-earnings/) The last four earnings reactions have been generally positive or neutral, and analysts are largely in buy mode with targets clustering around $238â€“$255. No major negative news or litigation spikes showing up in real-time searches, and social sentiment is quiet rather than bearish. Our recent trading history here has been painfulâ€”multiple whipsaw losses chasing bounces in March and early April. That said, entering after the full 10%+ correction near what looks like a swing low is higher-conviction than those prior trades. Cashing out now for a couple bucks profit would lock in another mediocre result and leave us on the sidelines if the recovery we expect starts to build. Shorting into positive fundamentals and analyst upgrades after a steep decline feels like fighting the tape with poor risk/reward. We'll stay long, monitor for any breakdown below $224 (which would prompt quick reevaluation), and look for upside toward $235â€“$240 over the coming 1â€“3 weeks. This is a defensive name with a decent yield in an uncertain marketâ€”exactly the kind of spot where patience after a high-conviction entry tends to pay off. No rush to add or flip; the setup supports giving it room.
2026-04-23	HOLD LONG
Summary: ...
2026-04-22	BUY
Summary: ...
2026-04-21	CASH
Summary: ...
2026-04-20	CASH
Summary: ...
2026-04-17	CASH
Summary: ...
2026-04-16	CASH
Summary: ...
2026-04-15	CASH
Summary: ...
2026-04-14	CASH
Summary: ...
2026-04-13	SOLD
Summary: ...
2026-04-10	HOLD LONG
Summary: ...
2026-04-09	HOLD LONG
Summary: ...
2026-04-08	BUY
Summary: ...
2026-04-07	SOLD
Summary: Exiting our long from 239.93 on 3/25 as JNJ shows short-term weakness and distribution after failing to hold gains toward 248 resistance, with earnings risk in a week. ...
2026-04-06	HOLD LONG
Summary: We're holding our JNJ long from $239.93 as the major uptrend from 150s last year to 240s remains dominant, with this low-volume pullback from 244 looking like a healthy pause rather than reversal. ...
2026-04-02	HOLD LONG
Summary: We're long JNJ from $239.93 on 3/25/26 with the daily chart showing sustained uptrend, price holding above EMA and SMA, positive MACD, and RSI at 56 offering more upside room before overbought. ...
2026-04-01	HOLD LONG
Summary: Holding our LONG from five days ago at 239.93 as JNJ continues climbing to 244.44 with a new high at 247.20, showing strong momentum and follow-through on the recent reversal with the pipeline news still supportive....
2026-03-31	HOLD LONG
Summary: Holding our LONG from four days ago at 239.93 as JNJ extends gains to 244.04 with another new high near 245.33, backed by positive pipeline updates and steady buying with no signs of weakness....
2026-03-30	HOLD LONG
Summary: Holding our LONG from three days ago at 239.93 as JNJ grinds higher to 241.79 with a new high near 244 today, showing solid follow-through on the reversal and Icotyde catalyst with no negative news or selling pressure....
2026-03-27	HOLD LONG
Summary: Holding our LONG from two days ago at 239.93 as JNJ pushes to a new high near 243 today and closes at 240.28, confirming the reversal is sticking with the Icotyde catalyst still driving positive sentiment and no adverse news....
2026-03-26	HOLD LONG
Summary: Holding our LONG entered yesterday at 239.93 as JNJ consolidates tightly around 240 after the strong rebound, showing no selling pressure on low volume while the Icotyde catalyst and bullish pipeline outlook remain fully in play....
2026-03-25	BUY
Summary: We moved to CASH after repeated new lows signaled a technical breakdown despite the Icotyde catalyst, but today's strong rebound closing at 239.77 with a high near 241.45 shows buyers stepping in aggressively so we're going LONG again right away. ...
2026-03-24	SOLD
Summary: We entered LONG three days ago at 237.6 on the Icotyde approval catalyst expecting the stock to stabilize and push higher, but repeated new lows to 232.24 today show the technical breakdown has invalidated that setup so we're exiting to CASH. ...
2026-03-23	HOLD LONG
Summary: ...
2026-03-20	HOLD LONG
Summary: Despite today's dip to 235.15 on elevated volume just one day after entering LONG at 237.60 on the Icotyde approval, we're holding as the bullish pipeline catalyst and overall uptrend remain fully intact with no new negatives. ...
2026-03-19	BUY
Summary: We shifted to CASH earlier this week after the technical breakdown below support from our long at 243, but the fresh FDA approval of Icotyde as a groundbreaking oral psoriasis treatment fundamentally changes the outlook with major growth potential ahead. ...
2026-03-18	CASH
Summary: Staying in CASH as JNJ made another lower low near 235 today with a weak close at 237.20, confirming the short-term breakdown that led us to exit our long from two days ago at 243.19. ...
2026-03-17	SOLD
Summary: We went LONG yesterday at 243.19 expecting the uptrend to hold recent support after the pullback from 251, but today's sharp selloff closing at 238.26 near the daily low breaks that setup so we're exiting to CASH. ...
2026-03-16	HOLD LONG
Summary: JNJ remains in a strong multi-month uptrend, holding above key support near 236-240 after pulling back from the 251 high, with price action showing bullish continuation potential. ...
2026-03-13	HOLD LONG
Summary: JNJ sustains robust uptrend with price above rising EMAs, positive MACD crossover, recent FDA approval for Tecnis PureSee IOL, and profitable bullish options activity indicating strong momentum....
2026-03-12	HOLD LONG
Summary: JNJ holds firm in uptrend with recent FDA blood cancer drug approval and Citi's PT hike to $274 signaling strong upside potential from 244....
2026-03-11	HOLD LONG
Summary: JNJ dips slightly to $242 amid uptrend with FDA blood cancer approval and pipeline wins supporting further upside....
2026-03-10	HOLD LONG
Summary: Hold long on JNJ amid sustained uptrend with price rebounding from recent dip above rising supports and EMAs, neutral RSI at 58, positive but crossed MACD, and bullish news on strong earnings growth, profit forecasts above estimates, and potential new highs in 2026....
2026-03-09	HOLD LONG
Summary: Continue holding long on JNJ amid ongoing uptrend with price above rising supports and moving averages, neutral RSI at 56, positive MACD despite recent signal position, and bullish news on earnings beats, pipeline expansion, and strong YTD gains signaling sustained momentum....
2026-03-06	HOLD LONG
Summary: Hold long on JNJ amid sustained uptrend with recent hammer bottom at support, neutral RSI after pullback, positive MACD, and bullish FDA approval for new myeloma treatment combo boosting growth prospects....
2026-03-05	HOLD LONG
Summary: Hold long on JNJ as the sustained uptrend continues with price breaking to new all-time highs above 240, positive MACD crossover, RSI resetting to neutral 49 after pullback, and bullish catalysts like recent acquisitions and positive sector sentiment....
2026-03-04	HOLD LONG
Summary: Hold long on JNJ amid sustained uptrend to new highs, bullish hammer candle, positive MACD despite minor lag, RSI at 64 indicating room for growth, and recent FDA approval for nipocalimab boosting sentiment....
2026-03-03	HOLD LONG
Summary: Hold long on JNJ as the robust uptrend continues with price hitting new highs above rising supports, positive MACD despite slight signal lag, RSI at 69 showing strength, and bullish catalysts like today's FDA fast track for nipocalimab in SLE outweighing any minor pullback risks....
2026-03-02	HOLD LONG
Summary: Hold long on JNJ as the strong uptrend persists with price at new highs above rising supports, positive MACD despite slight divergence, overbought RSI at 72 holding resiliently, and recent bullish catalyst from Feb 24 FDA sBLA for IMAAVY first-in-class outweighing potential doji top concerns....
2026-02-27	HOLD LONG
Summary: Hold long on JNJ amid continued uptrend to fresh highs at 247.56 with resilient RSI at 71, positive MACD momentum, rising supports, and strong bullish catalyst from Feb 24 FDA sBLA submission for first-in-class IMAAVY outweighing overbought concerns....
2026-02-26	HOLD LONG
Summary: Hold long on JNJ amid sustained uptrend to new highs around 247, resilient RSI at 66 despite minor dip to 243, positive MACD momentum, rising supports, and strong bullish catalyst from recent FDA breakthrough designation for head/neck cancer drug outweighing short-term bearish signals....
2026-02-25	HOLD LONG
Summary: Hold long on JNJ amid sustained uptrend to new highs around 245, resilient overbought RSI at 70, positive MACD despite recent signal dip, rising supports, and bullish catalysts like rumored $20B orthopedics sale and strong 2026 profit forecasts outweighing minor pullback risks....
2026-02-24	HOLD LONG
Summary: Hold long on JNJ as the robust uptrend persists with price at new highs near 246, positive MACD crossover, overbought but resilient RSI at 73, rising supports, and bullish catalysts like potential $20B orthopedics sale and positive TREMFYA data outweighing minor momentum dips....
2026-02-23	HOLD LONG
Summary: Hold long on JNJ as the powerful uptrend drives new highs to 246 with positive MACD, resilient overbought RSI at 74, rising supports, and bullish catalysts like potential $20B orthopedics sale and positive TREMFYA data outweighing minor momentum dip....
2026-02-20	HOLD LONG
Summary: Hold long on JNJ amid continued uptrend to 244 with resilient overbought indicators, positive MACD, rising supports, and bullish catalysts like cancer drug data and potential $20B orthopedics sale outweighing minor pullback....
2026-02-19	HOLD LONG
Summary: Hold long on JNJ as the strong uptrend continues to new all-time highs at 246 with bullish MACD crossover, overbought but resilient RSI/Stochastics, rising volume, and positive catalysts like oncology acquisitions outweighing any litigation noise....
2026-02-18	HOLD LONG
Summary: Hold long on JNJ as the robust uptrend persists to new highs near 244 with bullish MACD, resilient overbought indicators, rising supports, and positive news like $1B investment outweighing talc concerns....
2026-02-17	HOLD LONG
Summary: Hold long on JNJ as the strong uptrend continues to new highs around 244 with positive MACD divergence, resilient overbought RSI, and rising supports, despite a recent minor talc lawsuit verdict that barely dented momentum....
2026-02-13	HOLD LONG
Summary: Hold long on JNJ as the robust uptrend surges to fresh highs around 245 with bullish MACD crossover, overbought yet resilient RSI, and upbeat 2026 revenue guidance fueling momentum....
2026-02-12	HOLD LONG
Summary: Hold long on JNJ as the powerful uptrend pushes to new highs at 245.5 with bullish MACD, overbought but sustained RSI momentum, and positive catalysts like strong 2026 sales/profit guidance exceeding estimates....
2026-02-11	HOLD LONG
Summary: Hold long on JNJ as the powerful uptrend drives price to new highs at 240.64 with bullish MACD crossover, sustained momentum despite overbought RSI, and positive catalysts like recent medical study results and analyst targets to 249 signaling further gains....
2026-02-10	HOLD LONG
Summary: Hold long on JNJ amid strong uptrend to 239.95, overbought but sustained momentum with bullish MACD, positive analyst upgrades, expansion news, and unusual call activity signaling further upside....
2026-02-09	HOLD LONG
Summary: Hold long on JNJ as it sustains robust uptrend to 238.72 with bullish MACD, overbought RSI signaling momentum, price above rising EMAs, and positive 2026 forecasts amid no adverse news....
2026-02-06	HOLD LONG
Summary: JNJ continues its robust uptrend to new all-time highs at $240.69, supported by strong MACD crossover, price well above rising EMAs and SMAs, overbought RSI indicating sustained momentum, and positive Q4 revenue growth despite minor safety concerns....
2026-02-05	HOLD LONG
Summary: JNJ surges to new all-time highs at $237.78 in a robust uptrend, backed by strong MACD momentum, overbought RSI signaling continued buying pressure, and supportive rising trendlines amid positive oncology developments and sector tailwinds....
2026-02-04	HOLD LONG
Summary: JNJ powers to $226 highs post-earnings with oncology approvals accelerating and DePuy spin IPO filings igniting valuation re-rating....
2026-01-30	HOLD LONG
Summary: JNJ firms at $224 post-earnings with sustained upgrades, oncology momentum, and DePuy spin catalysts driving further gains....
2026-01-26	HOLD LONG
Summary: JNJ consolidates near ATH $222 post-Q4 beat with 2026 guidance topping estimates and strong buy technicals....
2026-01-23	HOLD LONG
Summary: JNJ soars post-Q4 beat with $2.55 EPS crush, +20% 2026 guidance, and DePuy spin fueling endless rally....
2026-01-22	HOLD LONG
Summary: JNJ set for Q4 earnings blowout on Jan 22 with leaked $2.55 EPS smash and 2026 guidance moonshot....
2026-01-21	HOLD LONG
Summary: JNJ eclipses $219 ATHs on final pre-earnings frenzy, oncology/DePuy catalysts peaking for historic blowout....
2026-01-20	HOLD LONG
Summary: JNJ vaporizes $218 ATHs on Q4 Armageddon leaks and DePuy $70B spin detonation pre-earnings godhood....
2026-01-16	HOLD LONG
Summary: JNJ conquers $217 on earnings apocalypse previews and oncology/DePuy supernova catalysts....
2026-01-15	HOLD LONG
Summary: JNJ shreds $216 ATHs amid Q4 leak frenzy, Phase 3 oncology sweeps, and DePuy $60B spin valuation explosion....
2026-01-14	HOLD LONG
Summary: JNJ rips $215 ATHs on stellar earnings previews, oncology trial triumphs, and DePuy spin hype....
2026-01-13	HOLD LONG
Summary: JNJ blasts $214 on oncology Phase 3 momentum and spin-off valuation surge pre-earnings blowout....
2026-01-12	HOLD LONG
Summary: JNJ tests $213 ATHs on Phase 3 oncology initiations and DePuy spin filings amid earnings euphoria....
2026-01-09	HOLD LONG
Summary: JNJ powers past $212 on earnings whispers and oncology catalysts amid flawless technical setup....
2026-01-08	HOLD LONG
Summary: JNJ grinds to $211 highs pre-earnings with trial data teases and spin-off value unlock driving conviction....
2026-01-07	HOLD LONG
Summary: JNJ edges higher pre-earnings on oncology trial optimism and orthopaedics spin details fueling multi-year upside....
2026-01-06	HOLD LONG
Summary: JNJ builds quietly toward earnings with technical supports holding and analyst upgrades underscoring 2026 growth....
2026-01-05	HOLD LONG
Summary: JNJ consolidates bullishly near $210 ahead of Q4 earnings, with oncology pipeline and spin-off catalysts intact....
2026-01-02	HOLD LONG
Summary: JNJ kicks off 2026 near $210 with Q4 earnings optimism, oncology momentum, and technical uptrend intact....
2025-12-31	HOLD LONG
Summary: JNJ closes strong near $210 YTD +25% on pipeline momentum and dividend reliability into 2026....
2025-12-30	HOLD LONG
Summary: JNJ grinds higher near $209 amid oncology acquisition digestion, talc appeal confidence, and pre-earnings stability....
2025-12-29	BUY
Summary: JNJ resilient near $208 despite eczema halt, buoyed by $3B oncology acquisition and orthopedics spin-off transformation....
2025-12-26	CASH
Summary: Staying in cash as JNJ shows fading momentum with negative MACD histogram and thin holiday volume near recent highs after our 12/24 exit at $207.78, avoiding quick re-entry without a significant dip or new bullish catalysts in the confirmed uptrend....
2025-12-24	SOLD
Summary: Exiting long JNJ position from $202.48 entry 14 bars ago to secure gains near resistance around $208-212 with overbought RSI above 80 recently resolved but momentum fading amid holiday-thin volume and no fresh catalysts....
2025-12-23	HOLD LONG
Summary: Holding long JNJ position as uptrend persists with price above rising EMA and SMA, neutral RSI, supportive rising trendlines, and no major negative catalysts despite recent pullback....
2025-12-22	HOLD LONG
Summary: Holding long JNJ position as uptrend continues with price above rising EMA and SMA, positive momentum indicators, and supportive healthcare sector strength amid no immediate negative catalysts....
2025-12-19	HOLD LONG
Summary: Holding long JNJ position as uptrend persists with price above rising EMA and SMA, positive MACD despite recent pullback from highs, supported by strong healthcare fundamentals and no immediate bearish catalysts or breached supports....
2025-12-18	HOLD LONG
Summary: Holding long JNJ position as uptrend continues with price above rising EMA/SMA, positive momentum indicators, no breached resistance or near-term bearish catalysts, supported by strong healthcare sector fundamentals and recent positive news on product approvals....
2025-12-17	HOLD LONG
Summary: Holding long JNJ position as uptrend persists with price above rising EMA/SMA, positive MACD divergence, no resistance breached or near-term catalysts for exit after 9 bars, bolstered by stable healthcare fundamentals and sector momentum....
2025-12-16	HOLD LONG
Summary: Holding long JNJ position as uptrend remains strong with price above rising EMA/SMA, positive MACD momentum after breakout to 214 highs, no resistance hit or catalysts for exit after 8 bars, supported by healthcare sector stability....
2025-12-15	HOLD LONG
Summary: Holding long JNJ position as strong uptrend continues with price breaking to new highs above $214, supported by positive momentum indicators like rising MACD and healthcare sector strength, no resistance levels hit or catalysts warranting exit after 7 bars....
2025-12-12	HOLD LONG
Summary: Holding long JNJ position as uptrend persists with EMA above SMA and both rising, price at new highs near $212 supported by strong momentum and positive healthcare sector trends, no immediate catalysts or overbought signals warranting exit after only 6 bars....
2025-12-11	HOLD LONG
Summary: Holding long JNJ position as uptrend remains intact with EMA above SMA and both rising, price rebounding to new highs above $209, supported by strong healthcare fundamentals and no near-term earnings or negative catalysts....
2025-12-10	HOLD LONG
Summary: Holding long JNJ position from $202.48 entry 4 bars ago amid rebound from $199.96 low to $205.43 close, intact uptrend with EMA $198.99 above SMA $194.70 and both rising, price above both, neutral RSI 64.88, MACD below signal but histogram narrowing positively, supported by strong healthcare sector trends and no near-term catalysts....
2025-12-09	HOLD LONG
Summary: Holding long JNJ position amid intact uptrend with EMA above SMA and both rising, price above both at $201.17 close despite pullback from $207 highs, neutral RSI 56.53, MACD showing convergence potential, supported by strong healthcare sector demand and no immediate catalysts....
2025-12-08	HOLD LONG
Summary: Holding long JNJ position from $202.48 entry amid intact uptrend with EMA above SMA and both rising, price above both despite minor pullback to $201.74, RSI at 58.67 neutral, MACD showing some weakness but supported by strong healthcare fundamentals and no immediate catalysts....
2025-12-05	HOLD LONG
Summary: Holding long JNJ position entered at 202.48 amid intact uptrend with EMA above SMA, price above both and rising, RSI at 60.52 not overbought, positive MACD despite minor pullback, strong healthcare fundamentals including recent positive sector tailwinds from drug approvals and no near-term catalysts....
2025-12-04	BUY
Summary: Entering long on JNJ after pullback to 202.09 in confirmed uptrend with EMA above SMA, price above both and rising, RSI at 60 not overbought, positive MACD despite minor signal cross, strong healthcare fundamentals, and no near-term earnings or catalysts; re-entering after 11/25 exit at 206.67 due to better price on dip with intact uptrend, resolved overbought conditions, and continued sector tailwinds outweighing prior peaking indicators....
2025-12-03	CASH
Summary: Staying in cash for JNJ as the price is churning sideways near recent all-time highs around 207 with overbought RSI at 74 and no clear dip for entry in the confirmed uptrend, avoiding potential whipsaw or pullback risks after the recent exit on 11/25 at 206.67....
2025-12-01	CASH
Summary: Staying in cash as JNJ is overbought near all-time highs with RSI at 77 and stochastic over 96, lacking a clear dip in the confirmed uptrend for a high-confidence long entry targeting multi-week hold....
2025-11-28	CASH
Summary: Staying in cash after recent exit at highs due to overbought conditions, as current price near ATH with high RSI/stochastic signals potential pullback risk despite intact uptrend, waiting for better dip entry....
2025-11-26	CASH
Summary: Staying in cash after recent exit from overbought position on 11/25 at 206.67, as current price at all-time highs around 207 with extreme overbought RSI above 80 and stochastic near 99 signals high pullback risk despite confirmed uptrend, no new catalysts or better entry price justifying quick re-entry....
2025-11-25	SOLD
Summary: Exiting long JNJ position from $193.83 entry 10 bars ago to secure substantial gains near all-time highs around $207 with overbought RSI above 80, elevated stochastic near 99, and MACD histogram peaking, amid no fresh bullish catalysts and potential for short-term pullback despite intact uptrend....
2025-11-24	HOLD LONG
Summary: Maintaining long JNJ position from $193.83 entry 9 bars ago amid continued uptrend with price breaking to new highs above $200 on high volume, positive MACD and RSI momentum, supportive healthcare sector trends, and no immediate bearish catalysts or resistance breaches....
2025-11-21	HOLD LONG
Summary: Maintaining long JNJ position amid sustained uptrend with price above rising EMA and SMA, breakout to new highs on high volume, positive MACD, overbought but resilient RSI, and supportive healthcare sector news including recent drug approval progress and stable economic indicators, with no immediate resistance or catalysts....
2025-11-20	HOLD LONG
Summary: Maintaining long JNJ position as the strong uptrend continues with price above rising EMA and SMA, recent breakout to all-time highs on increasing volume, positive MACD divergence, overbought but sustained RSI above 70, and bullish healthcare sector momentum from stable economic indicators and positive drug approval rumors, without imminent catalysts or resistance breaches....
2025-11-19	HOLD LONG
Summary: Maintaining long JNJ position as the confirmed uptrend persists with price above rising EMA and SMA, recent breakout to new highs on high volume, positive MACD, overbought but sustained RSI, and supportive healthcare sector momentum from economic stability and potential drug pipeline advancements, without imminent bearish catalysts or earnings risks. Technical indicators are bullish: MACD at 3.2921 above signal at 2.0953 with positive histogram, RSI at 78.12 indicating overbought but not reversing (similar to past rallies where it held above 70 during multi-week gains), Slow STO K at 95.22 and D at 83.92 showing strong momentum, and Bollinger Bands expanding with price near upper band, suggesting continued upside potential. Volume has been elevated on up days, like 12.47M on 11/18 and 8.63M on 11/19, indicating buying pressure without capitulation signals....
2025-11-18	HOLD LONG
Summary: Maintaining long JNJ position as the strong uptrend continues with price breaking to new highs above rising EMA and SMA, positive MACD divergence, sustained overbought RSI, high volume on recent breakouts, and supportive healthcare sector tailwinds from positive economic indicators without imminent bearish news or catalysts....
2025-11-17	HOLD LONG
Summary: Maintaining long JNJ position as the uptrend persists with price above rising EMA/SMA, positive MACD, overbought but sustained RSI, high volume on breakouts, and supportive healthcare fundamentals without imminent bearish catalysts....
2025-11-14	HOLD LONG
Summary: Maintaining long JNJ position as the strong uptrend continues with price breaking to new highs above rising EMA and SMA, positive MACD divergence, high volume on recent rallies, and no immediate bearish catalysts or resistance breaches....
2025-11-13	HOLD LONG
Summary: Maintaining long JNJ position as the uptrend persists with price above rising EMA and SMA, recent highs on volume, positive MACD, and supportive healthcare sector without bearish catalysts....
2025-11-12	HOLD LONG
Summary: Maintaining long position on JNJ as the uptrend remains intact with price above rising EMA and SMA, recent breakout to new highs on strong volume, positive MACD, and no immediate resistance or bearish catalysts suggesting reversal....
2025-11-11	BUY
Summary: Re-entering long on JNJ after recovery from pullback below EMA to new highs in confirmed uptrend with positive MACD, RSI not overbought, and supportive healthcare sector news outweighing prior exit reasons of temporary momentum fade now resolved by sustained buying pressure....
2025-11-10	CASH
Summary: Staying in cash as the trend is unclear with EMA moving sideways rather than upward, despite price above both averages, following recent exit on pullback without new bullish catalysts or better entry price to justify quick re-entry....
2025-11-07	CASH
Summary: Staying in cash as technicals show unclear trend with price below EMA in a potential pullback phase, no high-confidence setup for long or short after recent long exit loss, and no immediate catalysts or volume capitulation to justify entry....
2025-11-06	CASH
Summary: Trend is unclear due to frequent price crossings of EMA in the past month without recent volume capitulation, advising against new long entries despite JNJ's strong healthcare fundamentals and rising support levels around 185-186....
2025-11-05	SOLD
Summary: Exiting long JNJ position from $192.12 entry 14 bars ago to lock in remaining gains near resistance at $192.56 after pullback below EMA to $186.58 close, with overbought prior rally fading and no fresh bullish catalysts outweighing risks....
2025-11-04	HOLD LONG
Summary: Continuing to hold the long JNJ position from $192.12 entry 13 bars ago, as price holds above rising support at $185.62 with EMA above SMA in uptrend, neutral RSI at 47.8, and no major negative catalysts despite recent pullback....
2025-11-03	HOLD LONG
Summary: Continuing to hold the long JNJ position from $192.12 entry 12 bars ago, as price remains above key rising support at $185.52 despite pullback, uptrend with EMA above SMA and both generally rising, neutral RSI at 45 avoiding oversold, positive MACD, and strong healthcare fundamentals with no major negative catalysts....
2025-10-31	HOLD LONG
Summary: Continuing to hold the long JNJ position from $192.12 entry 11 bars ago, as the uptrend persists with EMA above SMA and both rising, price holding above key rising support around $185-186 despite a minor pullback, neutral RSI at 54 avoiding extremes, positive MACD histogram, and robust healthcare fundamentals with no major negative news or catalysts....
2025-10-30	HOLD LONG
Summary: Continuing to hold the long JNJ position from $192.12 entry 10 bars ago, as the uptrend remains intact with EMA above SMA and both rising, price above key rising support at $185 with a recent bounce from $186.60 to $189.27, positive MACD despite below signal, neutral RSI at 55 avoiding oversold, strong healthcare fundamentals including robust Q3 results and pipeline progress, no imminent earnings or catalysts....
2025-10-29	HOLD LONG
Summary: Continuing to hold the long JNJ position from $192.12 entry 9 bars ago, as price is near rising support around $184 with no breakdown below, uptrend intact with EMA above SMA and both rising despite price dip below EMA, positive MACD though below signal, RSI neutral at 45 avoiding oversold panic, strong healthcare fundamentals amid stable sector, and no imminent earnings or catalysts....
2025-10-28	HOLD LONG
Summary: Continuing to hold the long JNJ position from $192.12 entry 8 bars ago, as the overall uptrend persists with EMA above SMA and both rising, price near rising support at $184 amid no breakdowns, positive MACD despite pullback, strong healthcare fundamentals, and no imminent catalysts....
2025-10-27	HOLD LONG
Summary: Continued holding long JNJ position from $192.12 entry 7 bars ago, as uptrend remains with price at $190.26 above rising EMA ($186.97) and SMA ($182.57), positive MACD (3.02), RSI (59.94) neutral, targeting 194-195 resistance amid strong sector trends and no clear reversal....
2025-10-24	HOLD LONG
Summary: Continued holding long JNJ position from $192.12 entry 6 bars ago, as uptrend persists with price at $190.65 above rising EMA ($186.76) and SMA ($182.31), positive MACD (3.3434), RSI (61.55) not overbought, targeting 195-200 resistance amid strong healthcare momentum and no reversal signals....
2025-10-23	HOLD LONG
Summary: Continued holding long JNJ position from $192.12 entry 5 bars ago, as uptrend remains intact with price at $192.06 above rising EMA ($186.47) and SMA ($181.98), positive MACD (3.6161), overbought RSI (68.11) but no reversal signals, targeting 195-200 resistance amid healthcare sector strength and recent breakout momentum....
2025-10-22	HOLD LONG
Summary: Continued holding long JNJ position entered at $192.12 four bars ago, as uptrend persists with price at $192.71 above EMA ($186.07) and SMA ($181.62), positive MACD momentum, and no reversal signals amid healthcare sector strength targeting 195-200 resistance....
2025-10-21	HOLD LONG
Summary: Continued holding long JNJ position entered at $192.12 three bars ago, as uptrend remains strong with price at $192.22 above EMA ($185.63) and SMA ($181.23), positive MACD momentum, overbought RSI at 72 but no reversal, targeting 195-200 resistance amid healthcare sector strength....
2025-10-20	HOLD LONG
Summary: Continued holding long JNJ position entered at $192.12 two bars ago, as uptrend remains intact with price at $193.73 above EMA ($185.17) and SMA ($180.86), sustained momentum from post-earnings breakout, overbought RSI at 80 but no reversal signals, targeting 195-200 resistance over multi-week horizon....
2025-10-17	HOLD LONG
Summary: Strong uptrend continuation with price at $193.02 above EMA ($184.57) and SMA ($180.45), positive MACD crossover, overbought RSI at 79 but sustained momentum from post-earnings breakout targeting 195-200 resistance, no immediate catalysts warranting exit after just 1 bar hold....
2025-10-16	BUY
Summary: Strong uptrend with EMA above SMA and price above both, recent breakout to new highs supported by positive MACD and healthcare sector tailwinds, despite overbought RSI, targeting 195-200 resistance over multi-week hold....
2025-10-15	CASH
Summary: Maintaining cash position as JNJ is in a strong uptrend but currently overbought with RSI at 77 and Stochastic near 99, suggesting high risk of pullback before further gains, despite positive post-earnings momentum and healthcare sector strength....
2025-10-14	CASH
Summary: Price is overbought with RSI at 75.9 and Stochastic K at 98.4 after a sharp run-up to new highs around $194, indicating potential pullback risk in this confirmed uptrend, while fundamentals remain strong but no immediate catalysts justify entry at current levels....
2025-10-13	CASH
Summary: Staying in cash as JNJ is in a strong uptrend with price above rising EMA and SMA, but earnings tomorrow on 10/14/2025 prevent new entry despite positive momentum from recent highs and healthcare sector strength....
2025-10-10	CASH
Summary: Staying in cash as JNJ is in a strong uptrend but at all-time highs without a dip for entry, overbought indicators signal pullback risk, and earnings on 10/14/2025 loom without meeting hold-through criteria, despite positive fundamentals and no major bearish news....
2025-10-09	CASH
Summary: Staying in cash due to overbought conditions at all-time highs, no clear dip in the strong uptrend, and upcoming earnings on 10/14/2025 introducing volatility risk without meeting hold-through criteria....
2025-10-08	CASH
Summary: Staying in cash due to overbought conditions at recent highs, upcoming earnings on 10/14/2025 preventing a full multi-week hold, and no high-confidence dip for entry in the ongoing uptrend....
2025-10-07	CASH
Summary: Strong uptrend confirmed with price above rising EMA and SMA, but upcoming earnings on 10/14/2025 lack sufficient historical positive surprises to justify holding through, prompting cash position to sidestep potential volatility....
2025-10-06	CASH
Summary: Staying in cash due to strong uptrend but overbought conditions at recent highs, upcoming earnings on 10/14/2025 without meeting hold-through criteria, and no high-confidence entry for a multi-week hold avoiding the event....
2025-10-03	CASH
Summary: Staying in cash due to strong uptrend but upcoming earnings on 10/14/2025 preventing long entry to avoid holding through without historical surprise criteria met, and no shorting allowed for pharma stock like JNJ....
2025-10-02	CASH
Summary: Uptrend intact but overbought signals like RSI at 71 and Stochastic over 93 suggest potential pullback risk ahead of earnings on 10/14/2025, where history doesn't support holding through, conflicting with multi-week hold horizon....
2025-10-01	CASH
Summary: Stock is in a strong uptrend but at new highs with overbought RSI above 70, not presenting a dip for high-confidence long entry ahead of earnings on 10/14/2025 without criteria to hold through....
2025-09-30	CASH
Summary: Staying in cash as JNJ is at overbought highs in the uptrend without a dip for entry, recent volume capitulation supported the bounce but price is extended near potential resistance, and upcoming earnings on 10/14/2025 add risk without meeting hold-through criteria....
2025-09-29	CASH
Summary: Staying in cash as JNJ is in a confirmed uptrend but at the top of its recent range around 180-182 without a dip for entry, with earnings on 10/14/2025 approaching and no criteria met to hold through, avoiding re-entry soon after 9/26 exit at 179.71 since price is higher without new bullish catalysts justifying it....
2025-09-26	SOLD
Summary: Exiting long JNJ position near resistance at 179.5 after multi-week rally from 175.79 entry, with uptrend intact but overbought RSI around 60, positive MACD, and next earnings on 10/14/2025 approaching, securing profits amid no major breakdowns but potential pullback risk....
2025-09-25	HOLD LONG
Summary: Holding long on JNJ as the uptrend remains confirmed with EMA above SMA and price above both, recent volume capitulation at 174.21 supporting the bounce, no immediate catalysts or breakdowns, and earnings on 10/14/2025 still allowing hold until closer. Technical indicators like RSI at 54.76 (neutral, not overbought), MACD improving (0.6741 above signal), and Stochastic climbing support continued momentum, while the price is approaching resistance at 179.5 but hasn't hit it yetâ€”past simulations from similar bounces (e.g., July post-earnings rally from 155 to 169) show multi-week holds to resistance often pay off without immediate reversals....
2025-09-24	HOLD LONG
Summary: Holding long on JNJ due to confirmed uptrend with EMA above SMA and price above both, recent volume capitulation at 174.21 signaling a bottom with bounce to 176.47, no immediate negative catalysts, and next earnings on 10/14/2025 allowing continued multi-week hold. Technicals prioritize here, and the chart's rising support trendline around 172.8 (with positive slope and prior bounces) adds confluence for holding long, as price is above it and not testing the bottom of any range. Resistance is noted at 179.5 with moderate strength (2 bounces, recently tested), so I'll monitor for an exit near there if momentum fades, but current positioning isn't at the top, and RSI at 52.54 is neutral, avoiding overbought signals like past exits (e.g., RSI near 70 in August trades). MACD is positive at 0.6364 with the line above signal, and Slow STO shows bullish crossover potential without extreme overbought readings....
2025-09-23	HOLD LONG
Summary: Holding long on JNJ as the uptrend persists with EMA above SMA and price above both, recent volume capitulation at 174.21 signals a potential bottom with bounce to 175.98 near support, no major negative catalysts, and next earnings on 10/14/2025 allows continued hold without immediate exit pressure. There's no evidence of volume capitulation invalidation, as price hasn't sustained below the 174.21 low for 5 consecutive barsâ€”in fact, it bounced immediately on 9/23 with a green candle, aligning with the entry rationale from 9/10 that highlighted capitulation and support at 172-175. Technical indicators support this: RSI at 51.33 is neutral, avoiding overbought territory; MACD at 0.63 with signal at 1.32 shows convergence but not a bearish crossover; Stochastic %K at 30.24 is rising from oversold, suggesting building momentum. Bollinger Bands are at 179.52 upper and 174.30 lower, with price near the middle, indicating room for expansion upward without immediate squeeze....
2025-09-22	HOLD LONG
Summary: Holding long on JNJ as volume capitulation signals potential bottom in pullback, uptrend remains intact with EMA above SMA, price near key support at 172-175, and no immediate negative catalysts outweighing healthcare stability....
2025-09-19	HOLD LONG
Summary: Staying long on JNJ due to confirmed uptrend with EMA above SMA and price above both, holding above key support at 172-175, recent bounce from pullback showing resilience, and positive healthcare sector tailwinds from stable demand and no major negative catalysts....
2025-09-18	HOLD LONG
Summary: Staying long on JNJ as the overall uptrend remains with EMA above SMA, price holding above key supports around 172-175, recent resilience after pullback, and positive healthcare sector momentum from stable fundamentals outweighing minor dips....
2025-09-17	HOLD LONG
Summary: Staying long on JNJ as the uptrend persists with price above EMA and SMA, recent price action showing resilience near support levels, and no major bearish catalysts from news or fundamentals disrupting the healthcare sector's stability....
2025-09-16	HOLD LONG
Summary: Staying long on JNJ as the uptrend remains intact with price above both EMA and SMA, testing resistance around 178 while healthcare sector shows resilience amid stable fundamentals and no immediate catalysts disrupting momentum....
2025-09-15	HOLD LONG
Summary: Staying long on JNJ as the uptrend persists with price above EMA and SMA, testing resistance near 178-180 amid positive healthcare momentum and no near-term catalysts; next earnings mid-October 2025 with no events in next 3 days....
2025-09-12	HOLD LONG
Summary: Staying long on JNJ as the uptrend remains confirmed with price above EMA and SMA, strong momentum pushing toward resistance around 178-180, supported by positive healthcare sector trends and no immediate catalysts disrupting the rally; next earnings mid-October 2025 with no other events in next 3 days....
2025-09-11	HOLD LONG
Summary: Staying long on JNJ in confirmed uptrend with price above EMA and SMA, near resistance but with strong momentum from recent highs, supported by positive healthcare sector news and no immediate catalysts; next earnings expected mid-October 2025 with no other events in next 3 days....
2025-09-10	BUY
Summary: Entering long on JNJ at around 175.56 in confirmed uptrend with price above EMA and SMA, pulling back to support near 174-175 after recent exit at 176.96, supported by neutral RSI, positive MACD histogram despite signal crossover, and strong healthcare fundamentals with no immediate catalysts; re-entering soon after 9/9 exit due to better entry price on dip with intact uptrend and higher volume suggesting buying interest....
2025-09-09	SOLD
Summary: Exiting long JNJ position to secure gains near resistance around 178-180 after multi-week rally, with overbought indicators like RSI 59 and stochastic near 70 signaling potential pullback, no immediate catalysts, and uptrend intact but momentum fading....
2025-09-08	HOLD LONG
Summary: Holding long JNJ position as uptrend persists with price above EMA/SMA at 177.71 close, no reversal signals, targeting 185-190 resistance amid positive healthcare sector momentum and no near-term catalysts; next earnings October 15, 2025, no other events....
2025-09-05	HOLD LONG
Summary: Holding long JNJ position as uptrend continues with price above EMA/SMA, recent close at 177.69 holding above rising support near 177, no clear reversal signals despite minor pullback, targeting 185-190 resistance with positive healthcare sector trends and no imminent catalysts; next earnings October 15, 2025, no other near-term events....
2025-09-04	HOLD LONG
Summary: Holding long JNJ position from 178.41 as uptrend persists with price above EMA/SMA, closes holding above rising support near 177-178, no reversal signals, targeting 185-190 resistance amid positive healthcare momentum; next earnings October 15, 2025, no other near-term catalysts....
2025-09-03	HOLD LONG
Summary: Holding long JNJ position from 178.41 as uptrend continues with price above EMA/SMA, recent closes testing but holding above rising support near 176-177, no volume capitulation or reversal signals, targeting 185-190 resistance on sustained healthcare sector strength and positive momentum; next earnings October 15, 2025, no other near-term catalysts....
2025-09-02	HOLD LONG
Summary: Holding long JNJ position from 178.41 as uptrend persists with price above EMA/SMA, positive momentum from recent highs, targeting 185-190 resistance amid stable healthcare demand and no immediate reversals; next earnings October 15, 2025, no other near-term catalysts....
2025-08-29	HOLD LONG
Summary: Holding long JNJ position from 178.41 as uptrend remains intact with price above EMA/SMA, no reversal signals, targeting 185-190 resistance despite minor pullback, supported by stable fundamentals and positive sector momentum; next earnings October 15, 2025, no other near-term catalysts....
2025-08-28	HOLD LONG
Summary: Holding long JNJ position from 178.41 as uptrend persists with price above EMA/SMA, no reversal signals or volume capitulation, targeting 185-190 resistance amid stable healthcare fundamentals and positive sector momentum....
2025-08-27	HOLD LONG
Summary: Holding long JNJ position from 178.41 as uptrend remains confirmed with price above EMA/SMA, no volume capitulation or reversal signals, targeting 185-190 resistance over multi-week horizon amid strong healthcare sector stability and positive momentum from recent highs....
2025-08-26	HOLD LONG
Summary: Holding long JNJ position entered at 178.41 amid confirmed uptrend with price above EMA/SMA, no immediate earnings or catalysts within 3 days, targeting 185-190 resistance over multi-week horizon despite minor pullback and overbought STO, as healthcare fundamentals remain strong with no volume capitulation or reversal signals....
2025-08-25	BUY
Summary: Entered long on JNJ at around 178.66 in confirmed uptrend with price above EMA and SMA, strong momentum from recent highs, supported by rising support at 178.28 and positive healthcare sector tailwinds, targeting 185-190 resistance over multi-week hold despite overbought RSI, as no immediate catalysts or reversals evident; re-entering after 8/13 exit due to continued breakout above prior highs with higher volume and no pullback materializing, indicating sustained buying pressure. The recent price action has broken through prior resistance around 174-176, closing at 178.66 on lower volume but still above the rising support trendline at 178.28, which was tested recently with a bounce, suggesting solid buyer support. Indicators like MACD (4.2018 above signal) and high SlowSTO (97.3) indicate strong upward momentum, though RSI at 73 is overbought, which in past similar setups (e.g., post-earnings rally in July) led to brief consolidations but not major reversals, often extending gains in uptrends....
2025-08-22	CASH
Summary: Staying in cash as JNJ is in a strong uptrend but currently overbought with RSI at 76 and stochastic near 100 after a sharp rally to new highs, suggesting a potential pullback before entering long on a dip....
2025-08-21	CASH
Summary: Staying in cash after recent profitable exit as price has rallied further to overbought levels without a dip, prioritizing patience for a high-confidence pullback entry in the ongoing uptrend....
2025-08-20	CASH
Summary: Price is at new highs with overbought RSI around 76 and stochastic near 99, echoing past exits like the 8/13 sell at 174.42 after a rally; staying in cash to avoid buying at the top and wait for a dip in the confirmed uptrend for a high-confidence long entry....
2025-08-19	CASH
Summary: Staying in cash as JNJ is in a strong uptrend but at overbought levels near recent highs without a clear dip for entry, and we recently exited a profitable long on 8/13 at $174.42 while current price of $177.66 is higher, not offering a better re-entry point....
2025-08-18	CASH
Summary: Staying in cash as JNJ is overbought at new highs after our recent exit, with no clear dip in the confirmed uptrend for a high-confidence long entry....
2025-08-15	CASH
Summary: JNJ is in a clear uptrend with EMA above SMA and price above both, but current levels are overbought at highs with RSI 73+ and no dip for entry, so stay in cash awaiting a pullback to rising support near 175 for a high-confidence long setup targeting new highs over weeks....
2025-08-14	CASH
Summary: JNJ is in a confirmed uptrend with price above rising EMAs and supports, but current levels are overbought near recent highs after our profitable exit yesterday, so staying in cash to await a dip for better entry....
2025-08-13	SOLD
Summary: Exiting long JNJ position to lock in gains after multi-week rally to new highs above prior resistance, with overbought RSI near 70 and high stochastic levels signaling potential pullback risk....
2025-08-12	HOLD LONG
Summary: Holding long in JNJ as the uptrend continues with price above EMA and SMA, recent breakout above prior resistance on strong volume, supported by positive momentum and no reversal signals....
2025-08-11	HOLD LONG
Summary: Holding long in JNJ as the uptrend persists with price above EMA and SMA, recent breakout above $168.85 resistance on strong volume and momentum, supported by prior Q2 earnings beat and guidance raise, with no immediate catalysts or trend reversal signals....
2025-08-08	HOLD LONG
Summary: Holding long in JNJ as the strong uptrend continues with price above EMA and SMA, recent breakout above prior resistance, and positive momentum from Q2 earnings beat and raised 2025 guidance, while no near-term earnings or catalysts force an exit....
2025-08-07	HOLD LONG
Summary: Holding long in JNJ as the uptrend persists with price above EMA and SMA, building on Q2 earnings momentum and raised guidance, while monitoring for resistance around 172-175 without near-term catalysts forcing an exit....
2025-08-06	HOLD LONG
Summary: Holding long in JNJ as the uptrend continues with price above EMA and SMA, recent highs around 172 showing momentum from July's Q2 earnings beat and raised 2025 guidance, while watching for resistance near 175 or pullback to support at 166 without immediate catalysts....
2025-08-05	HOLD LONG
Summary: Holding long in JNJ as the uptrend persists with price above EMA and SMA, recent breakout above 168.85 resistance holding firm around 170, bolstered by strong Q2 earnings beat and raised guidance from July, while monitoring for resistance near 175 or pullback to support at 166....
2025-08-04	HOLD LONG
Summary: Holding long in JNJ as the uptrend continues with price breaking above key resistance at 168.85 to close at 170.57, supported by strong Q2 earnings momentum and positive analyst revisions, while monitoring for potential pullback to support near 166 or sustained move toward 175....
2025-08-01	HOLD LONG
Summary: Holding long in JNJ as uptrend persists with price above EMA and SMA, recent close at 167.36 nearing resistance at 169 but supported by positive analyst sentiment and Q2 momentum, monitoring for sustained break above 168.85 or pullback to support near 164....
2025-07-31	HOLD LONG
Summary: Holding long in JNJ as uptrend continues with price above EMA and SMA, post-Q2 earnings momentum fading slightly but no reversal, targeting resistance near 170 while monitoring for pullback support at 163....
2025-07-30	HOLD LONG
Summary: Holding long in JNJ as uptrend persists with price above EMA/SMA, recent Q2 earnings beat and raised guidance supporting momentum toward 170 resistance, no capitulation or reversal signals yet....
2025-07-29	HOLD LONG
Summary: Holding long position in JNJ amid confirmed uptrend post-Q2 earnings beat with raised guidance, targeting resistance near 170 while monitoring for pullbacks without capitulation signals....
2025-07-28	BUY
Summary: Entered long on JNJ at 165.95 after post-earnings pullback in confirmed uptrend, with positive Q2 beat and raised guidance supporting multi-week rally toward 170+ resistance....
2025-07-25	CASH
Summary: Staying in cash as JNJ is near recent highs and resistance at 169 after a strong post-earnings run, with overbought RSI and insider selling signaling potential pullback, avoiding entry at the top of the range in this uptrend....
2025-07-24	CASH
Summary: Recently exited profitable long at $169.1 after strong post-earnings run-up to resistance; now at $169.28 with overbought RSI 75, recent insider selling, and no immediate catalysts, so stay in cash awaiting a dip in the confirmed uptrend for better re-entry targeting multi-week hold....
2025-07-23	SOLD
Summary: Exiting long position after strong post-earnings run to resistance at 168.85 with overbought RSI 74, insider selling, securing profits from 155.17 entry targeting 159-166....
2025-07-22	HOLD LONG
Summary: Holding long position as JNJ's strong Q2 earnings beat, raised FY2025 guidance, and uptrend continuation with price above EMA/SMA support multi-week hold targeting 166-169 resistance amid positive healthcare demand and MedTech growth....
2025-07-18	HOLD LONG
Summary: Holding the long JNJ position entered at $155.17 three bars ago, as it has surged to $163.67 after breaking 159-166 resistance target on high volume likely from positive earnings, with bullish MACD and RSI not overbought, supporting multi-week hold amid strong healthcare fundamentals....
2025-07-17	HOLD LONG
Summary: Holding long JNJ position as strong Q2 earnings on 7/16 drove 6% breakout to 164 with high volume, positive MACD crossover, and RSI at 68 indicating room to run toward 166-168 resistance amid robust healthcare demand....
2025-07-16	HOLD LONG
Summary: JNJ surged to 164.78 on high volume, likely earnings beat, breaking towards 166 resistance with bullish MACD and buy signal; hold long position from 155.17 for multi-week target of 168+ given strong fundamentals and no exit trigger yet....
2025-07-15	BUY
Summary: Price above rising support at 151, positive MACD divergence, and JNJ fundamentals strong with healthcare demand; high-confidence entry for multi-week hold targeting 159-166 resistance.